Earnings double in 4 years ![]()
Continuing with conservative forecasts. Explosive earnings growth is coming in the next few years.
Earnings double in 4 years ![]()
Continuing with conservative forecasts. Explosive earnings growth is coming in the next few years.
Why have you chosen that specific analysis from April 25, 2021, as the starting point for your review? After all, Inderes has been covering Revenio for ages, and the forecasts have hit the mark quite well. I took a spot-check look at Mikaelâs report from February 16, 2018, for example; in it, the EBIT trajectory is quite solid even up to this day ![]()
Is that the problem you see in the chart? ![]()
You can look at the matter in so many ways. Even the fact that Mikael made good forecasts in 2017 is true. I just donât bother to write it in every post.
I didnât say there was a problem, I was mainly wondering why the forecast history doesnât go further back, since those forecasts are available; it would give a fairer picture of Inderesâ long-term forecast accuracy. Otherwise, it creates a recency bias ![]()
Mikael stopped making Revenio forecasts in 2021. I donât believe that forecasts made by Mikael more than five years ago help with future forecasts. And yes, there is other informational value in that image besides whether those forecasts hit the mark. It is clear that they didnât.
In my opinion, Revenio offers the best buying opportunity since spring 2019, when the CenterVue acquisition was made. The valuation has been pushed down, but at the same time, the market position and relative performance vs. competitors are first-class. I believe Revenio is executing its strategy very purposefully, supported by a committed and long-term principal owner. The acquisition card (even in the very short term) makes owning it interesting at this point, if/when the product portfolio and consequently the target market can be expanded. And surely the company has products/services in development in its own pipeline that we arenât even aware of yet. Now you get growing quality at a reasonable price, and you can no longer claim that âRevenio is always expensive.â
So, is your point with that image a) forecasting is difficult, especially predicting the future, or b) do you think the current analyst is performing so poorly that the analyst should be replaced?
If itâs a), I strongly agree with that; especially in recent years (3-5y), forecasting economic development has been devilishly difficult.
Everyone can interpret those images however they like. In my opinion, one can draw very clear conclusions about future forecasts from them, but Iâm not claiming that anyone needs to reach the same conclusions, even though I think itâs sensible to utilize that information.
The companyâs valuation is lower than ever, at least. The cash position is strong and cash flow for the full year is good. Q4 was admittedly quite poor. Hopefully, these are temporary problems.
iCare partners with Mediwhale to utilize AI focused on the prevention of cardiovascular diseases
Edit: âThe aim of the partnership is to integrate Mediwhaleâs AI-based Dr. Noon CVD software, which predicts the risk of cardiovascular diseases using retinal images, into the iCare DRSplus fundus camera as part of the iCare Screening Solution. This creates an effective combined solution for preventive healthcare.â